Ergosta-4,6,8(14),22-tetraen-3-one exhibits cytotoxic activity against human gastric cancer cells and can induce G2 M cell cycle arrest and apoptosis in human hepatocellular carcinoma (HepG2) cells, offering potential for future therapeutic applications in humans.